Mesoblast Ltd (MESO) Stock Analysis
Verdict: HOLD
Aggressive insider buying and a transition to commercial-stage revenue validate the platform, but the clinical-to-commercial execution risk remains high.
Investment score: 62/100
Analysis as of
Is Mesoblast Ltd stock worth reviewing? The TradeMates thesis
Mesoblast is at a critical inflection point. While fundamentals remain objectively poor (deeply negative margins), the technical momentum and $161M cash cushion suggest a shift in market sentiment from 'survival' to 'expansion'. The model suggests holding to see if commercial revenue can match the 2027-2029 hockey-stick projections ($0.2B to $0.6B).
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 95/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Mesoblast Ltd opportunities and risks
What speaks for MESO
- Commercial Inflection Point
What speaks against MESO
- Commercial Execution Failure
Peers and competitors
- CSL.AX
- TLX.AX
- MSB.AX
- PYC.AX
- CUV.AX
Frequently asked questions about Mesoblast Ltd (MESO)
Is MESO stock a good investment?
The TradeMates model rates Mesoblast Ltd as HOLD with an investment score of 62/100. Mesoblast is at a critical inflection point. While fundamentals remain objectively poor (deeply negative margins), the technical momentum and $161M cash cushion suggest a shift in market sentiment from 'survival' to 'expansion'. The model suggests holding to see if commercial revenue can match the 2027-2029 hockey-stick projections ($0.2B to $0.6B). This is algorithmic model output, not personal investment advice.
Is MESO stock a buy?
The TradeMates model verdict for MESO is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.